This bill, titled the "United States-Abraham Accords Cooperation and Security Act of 2025," mandates the establishment of an Abraham Accords Office within the Food and Drug Administration (FDA). This new office, to be headed by a director, will be located in an Abraham Accords country within two years of the bill's enactment, following consultations with relevant governments and U.S. diplomatic and security personnel. The office's primary duties include providing technical assistance to regulatory partners in Abraham Accords countries, focusing on strengthening regulatory oversight and converging requirements for regulated products, such as good manufacturing practices for medical products. It will also facilitate interactions between the FDA and interested parties in these countries, sharing information on U.S. regulatory pathways and gathering feedback on product research, development, and manufacturing. Furthermore, the bill requires a report to Congress within three years, evaluating the office's progress, interactions facilitated, and technical assistance provided, along with recommendations for improving coordination.